$3.87
+0.03 (+0.78%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where FULC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 5 with posted results
Held by 14 tracked-famous managers (D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd, RENAISSANCE TECHNOLOGIES LLC, +9 more) · FINRA short interest 4.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101NCT07401823Number of participants reporting Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Pociredir | Sickle Cell Disease | 50 | 2030-02-04 | in 1,265 d | 2026-04-14 |
| Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell DiseaseNCT07431398Plasma concentration of pociredir under fasted and fed conditionsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: Pociredir | Sickle Cell Disease | 13 | 2026-06-01actual | — | 2026-06-18 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PociredirNCT05169580Treatment-Emergent Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: Pociredir oral capsule(s) | Sickle Cell Disease, Sickle Cell Anemia | 45 | 2026-01-20actual | — | 2026-02-12 |
| Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)NCT05397470results2025-11-10Part A: Change From Baseline in Total Relative Surface Area (RSA) Quadrants 1 to 5 (Q1-Q5) With 500 Grams (g) Wrist Weight Averaged Over Both Arms as Assessed by Reachable Workspace (RWS) at Week 48Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Losmapimod, Placebo oral tablet | Facioscapulohumeral Muscular Dystrophy (FSHD) | 260 | 2024-11-19actual | — | 2025-11-10 |
| Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)NCT04264442results2025-09-30Number of Participants Reporting Serious Treatment Emergent Adverse Events (Serious TEAEs) and TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Losmapimod | Facioscapulohumeral Muscular Dystrophy (FSHD) | 76 | 2024-11-07actual | — | 2025-09-30 |
| Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionNCT04004000results2025-12-02Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Losmapimod | Facioscapulohumeral Muscular Dystrophy 1 | 14 | 2024-10-31actual | — | 2025-12-02 |
| Safety, Tolerability and Pharmacokinetics of FTX-6058NCT04586985Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: FTX-6058/placebo oral capsule(s), FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup, FTX-6058/placebo oral capsule(s) | Healthy Adult Subjects, Sickle Cell Disease | 109 | 2022-11-15actual | — | 2022-12-12 |
| Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsNCT05002231Plasma Concentrations of LosmapimodRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet | Healthy Adult Subjects | 18 | 2021-10-05actual | — | 2021-11-12 |
| Losmapimod Safety and Efficacy in COVID-19NCT04511819results2024-03-13Percentage of Participants Who Progressed to Death or Respiratory Failure by Day 28Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to the rapidly evolving environment for the treatment of Covid-19 and ongoing challenges to identify and enroll qualified patients to participate. | Drug: Losmapimod oral tablet, Placebo oral tablet | COVID-19 | 52 | 2021-03-31actual | — | 2024-03-13 |
| Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT04003974results2024-07-10Change From Baseline in Double Homeobox 4 (DUX4) Activity in Affected Skeletal MuscleRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Losmapimod oral tablet, Placebo oral tablet | Facioscapulohumeral Muscular Dystrophy (FSHD) | 80 | 2021-01-28actual | — | 2024-07-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19